| Entry |
|
|---|
| Name |
Methylergonovine maleate (USP);
Methylergometrine maleate (JP18);
Methergine (TN) |
|---|
| Product |
|
|---|
| Generic |
METHERGINE (Lupin Pharmaceuticals), METHYLERGONOVINE MALEATE (American Health Packaging), METHYLERGONOVINE MALEATE (American Regent), METHYLERGONOVINE MALEATE (Breckenridge Pharmaceutical), METHYLERGONOVINE MALEATE (Bryant Ranch Prepack), METHYLERGONOVINE MALEATE (Bryant Ranch Prepack), METHYLERGONOVINE MALEATE (Granules Pharmaceuticals), METHYLERGONOVINE MALEATE (HF Acquisition Co LLC), METHYLERGONOVINE MALEATE (Major Pharmaceuticals), METHYLERGONOVINE MALEATE (Rising Pharma Holdings), METHYLERGONOVINE MALEATE (Teva Pharmaceuticals USA), METHYLERGONOVINE MALEATE (Volley Pharmaceuticals) |
|---|
| Formula |
C20H25N3O2. C4H4O4
|
|---|
| Exact mass |
455.2056
|
|---|
| Mol weight |
455.50
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01964 Ergot alkaloid
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2531 |
| Product (DG00445): | D00680<JP/US> |
|
|---|
| Efficacy |
Hemostatic, Oxytocic |
|---|
| Comment |
Ergot alkaloid
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G02 OTHER GYNECOLOGICALS
G02A UTEROTONICS
G02AB Ergot alkaloids
G02AB01 Methylergometrine
D00680 Methylergonovine maleate (USP) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
253 Oxytocics
2531 Ergots
D00680 Methylergonovine maleate (USP); Methylergometrine maleate (JP18)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01964 Ergot alkaloid
DG00445 Methylergometrine
D00680 Methylergonovine maleate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00445 Methylergometrine
D00680 Methylergonovine maleate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D00680 Methylergonovine maleate (USP) <JP/US>
ADRA2
D00680 Methylergonovine maleate (USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00680 Methylergometrine maleate
D00680 Methylergometrine maleate tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00680
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01964 Ergot alkaloid
DG00445 Methylergometrine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00445 Methylergometrine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 33
1 C8y C 16.2515 -18.1993
2 C8y C 16.2515 -16.8352
3 C8y C 17.4232 -18.8696
4 C8y C 15.0681 -18.8696
5 C2y C 17.4291 -16.1648
6 C8x C 15.0741 -16.1590
7 C1x C 18.5949 -18.2110
8 C8x C 17.4232 -20.2336
9 N4x N 15.0681 -20.2336
10 C8x C 13.8965 -18.1993
11 C1y C 18.6065 -16.8410
12 C2x C 17.4291 -14.8066
13 C8x C 13.8965 -16.8352
14 N1y N 19.7725 -16.1648
15 C1y C 18.6065 -14.1304
16 C1x C 19.7725 -14.8066
17 C1a C 20.9558 -16.8410
18 C5a C 18.6124 -12.7780
19 N1b N 19.7899 -12.1019
20 O5a O 17.4348 -12.0959
21 C1c C 20.9499 -12.7664
22 C1b C 22.1216 -12.0959
23 C1b C 20.9495 -14.1610
24 C1a C 23.3267 -12.7978
25 O1a O 22.1572 -14.8585
26 C6a C 29.0135 -16.5578
27 C2b C 28.3275 -15.3818
28 O6a O 28.3333 -17.7394
29 O6a O 30.3718 -16.5518
30 C2b C 26.6970 -15.3875
31 C6a C 26.0238 -16.5693
32 O6a O 24.6584 -16.5693
33 O6a O 26.7087 -17.7451
BOND 35
1 5 11 1
2 5 12 2
3 6 13 1
4 11 14 1
5 12 15 1
6 14 16 1
7 14 17 1
8 15 18 1 #Up
9 18 19 1
10 18 20 2
11 19 21 1
12 21 22 1
13 7 11 1
14 8 9 1
15 10 13 2
16 15 16 1
17 21 23 1 #Up
18 22 24 1
19 1 2 1
20 23 25 1
21 1 3 1
22 1 4 2
23 2 5 1
24 2 6 2
25 3 7 1
26 3 8 2
27 4 9 1
28 4 10 1
29 26 27 1
30 26 28 1
31 26 29 2
32 27 30 2
33 30 31 1
34 31 32 1
35 31 33 2
|
|---|
